Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT?

Affiliations

¹ Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada.
² Inserm U954 and Department of Hepato-Gastroenterology, Université de Lorraine, Vandœuvre-lès-Nancy, France.
³ Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.

Editorial

Neeraj Narula et al. Gastroenterology. 2014 Mar.

. 2014 Mar;146(3):608-11.

doi: 10.1053/j.gastro.2014.01.040. Epub 2014 Jan 24.

¹ Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada.
² Inserm U954 and Department of Hepato-Gastroenterology, Université de Lorraine, Vandœuvre-lès-Nancy, France.
³ Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.

No abstract available

Comment on

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.
Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, Bourdages R, Macintosh DG, Dallaire C, Cohen A, Fedorak RN, Paré P, Bitton A, Saibil F, Anderson F, Donner A, Wong CJ, Zou G, Vandervoort MK, Hopkins M, Greenberg GR. Feagan BG, et al. Gastroenterology. 2014 Mar;146(3):681-688.e1. doi: 10.1053/j.gastro.2013.11.024. Epub 2013 Nov 21. Gastroenterology. 2014. PMID: 24269926 Clinical Trial.